S309 is a monoclonal antibody that targets the spike (S) glycoprotein of SARS-CoV-2. It potently neutralizes SARS-CoV-2 and SARS-CoV by binding a conserved glycan-containing epitope in the receptor-binding domain, without blocking receptor attachment. S309 has demonstrated strong neutralization alone and in antibody cocktails, offering potential for prophylaxis and post-exposure therapy.
Species reactivity
SARS-CoV-2(2019-nCoV), SARS-CoV
Applications
ELISA, Neutralization
Host species
Human
Isotype
IgG1, kappa
Clone ID
S309
Clonality
Monoclonal
Target
Spike glycoprotein, S glycoprotein, E2, Peplomer protein, RBD, Spike protein S1, S, Receptor-Binding Domain
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Caption
SEC-HPLC detection for InVivoMAb Anti-SARS-CoV-2 RBD Antibody (S309).,Detects SARS-CoV-2 RBD (KP.2 variant) in indirect ELISA. | SDS-PAGE for InVivoMAb Anti-SARS-CoV-2 RBD Antibody (S309).
Note
For research use only. Not suitable for clinical or therapeutic use.
抗体
试剂盒
多肽
蛋白
组织芯片
定制服务咨询